Efficacy of 5-Hydroxytryptophan, Niacin, and Pyridoxine in Mild to Moderate Depression: A Prospective Clinical Study
S.Rasheed, I. Dogar, D. Fatima, H. Yazdani
Abstract
Objective
To evaluate the efficacy of a fixed-dose combination of 5-hydroxytryptophan (5-HTP), niacin, and pyridoxine in adults with mild to moderate depression.
Methods
This prospective, non-randomised interventional study was conducted in a tertiary-care psychiatry outpatient department. Adults aged 18–65 years meeting DSM-5 criteria for mild to moderate major depressive disorder were enrolled. Participants received oral 5-HTP (100 mg), niacin (5 mg), and pyridoxine (2 mg) daily for 12 weeks. Depression severity was assessed using the 17-item Hamilton Depression Rating Scale (HAM-D17).
Results
Of 185 enrolled participants, 99 (53.5%) completed 12-week follow-up. Mean HAM-D17 scores decreased significantly from 16.8 ± 4.3 at baseline to 3.9 ± 4.6 at week 12 (p < 0.001). Clinical response occurred in 83.8% and remission in 61.6% of completers.
Conclusions
The supplement combination was associated with significant symptomatic improvement in mild to moderate depression. Randomised controlled trials are required to confirm efficacy.
Keywords
Depression; 5-hydroxytryptophan; Niacin; Pyridoxine; Nutraceuticals; HAM-D
Introduction
Depression is among the leading causes of global disability and is associated with reduced quality of life, increased healthcare utilisation, and suicide risk [1,2,3]. Although selective serotonin reuptake inhibitors (SSRIs) are widely prescribed, delayed onset of action, adverse effects, incomplete remission, and high relapse rates remain substantial limitations [4,5,6].
5-Hydroxytryptophan (5-HTP), the immediate precursor of serotonin, bypasses the rate-limiting step of tryptophan hydroxylation and may enhance central serotonergic activity. Pyridoxine (vitamin B6) acts as a cofactor in serotonin synthesis, while niacin (vitamin B3) supports neuronal energy metabolism via NAD/NADP pathways [8–10]. Deficiencies of B vitamins have been associated with depressive symptoms and impaired neurocognitive function [11,12,13,14]. Despite growing interest in nutraceutical approaches, evidence on the combined efficacy of these agents remains limited. This study aimed to evaluate the effectiveness of a standardised combination of 5-HTP, niacin, and pyridoxine in mild to moderate depression.
In recent years, increasing attention has been directed toward nutritional and metabolic contributors to depression, particularly in populations where micronutrient deficiencies are prevalent and access to psychiatric care is limited. Emerging evidence suggests that disturbances in monoamine synthesis, mitochondrial dysfunction, and elevated homocysteine levels may interact to exacerbate depressive symptoms, especially in early or less severe illness stages [11, 12, 13, 14]. Nutraceutical interventions targeting these pathways may therefore offer a pragmatic adjunct or alternative to conventional pharmacotherapy, with potential advantages in tolerability, cost, and patient acceptability. However, clinical data evaluating combined serotonin precursors and vitamin cofactors in well-defined depressive populations remain scarce, underscoring the need for systematic investigation.
Methods
Study Design and Setting
This prospective, non-randomised clinical trial was conducted in the outpatient psychiatry department of DHQ/Allied Hospital-II, Faisalabad Medical University, over six months following ethical approval.
Participants
Adults aged 18–65 years newly diagnosed with major depressive disorder according to DSM-5 criteria were included. Depression severity was classified as mild to moderate using baseline HAM-D17 scores. Exclusion criteria included severe depression, comorbid psychiatric disorders, current antidepressant use, pregnancy or lactation, history of serotonin syndrome, and medical conditions affecting serotonin metabolism.
Intervention
Participants received once-daily oral capsules containing:
• 5-HTP 100 mg
• Niacin 5 mg
• Pyridoxine 2 mg
The intervention duration was 12 weeks.
Outcome Measures
The primary outcome was change in HAM-D17 score from baseline to week 12. Secondary outcomes included:
• Response: ≥50% reduction in HAM-D17
• Remission: HAM-D17 ≤7
• Clinical Global Impression–Severity CGI-S) in a subset of participants
• Adverse events
Statistical Analysis
Data were analysed using SPSS v23. Continuous variables were expressed as mean ± SD and categorical variables as frequencies and percentages. Paired t-tests assessed pre–post changes in HAM-D17 scores. Chi-square tests examined associations between socio-demographic variables and treatment response. Statistical significance was set at p ≤ 0.05.
Results
Baseline Characteristics
A total of 185 participants were enrolled (mean age 38.5 ± 13.4 years), with females comprising 74.1%. Baseline mean HAM-D17 score was 16.3 ± 4.5.
Table 1: Baseline Socio-demographic and Clinical Characteristics (n = 185)
| Variable | Category | n (%) / Mean ± SD |
| Age (years) | Mean ± SD | 38.5 ± 13.4 |
| Gender | Female | 137 (74.1) |
| Male | 48 (25.9) | |
| Residence | Urban | 111 (60.0) |
| Rural | 74 (40.0) | |
| Marital status | Married | 108 (58.4) |
| Single | 41 (22.2) | |
| Divorced/ Widowed | 36 (19.5) | |
| Education | ≤ Primary | 79 (42.7) |
| ≥ Middle | 106 (57.3) | |
| Socioeconomic status | Low | 101 (54.6) |
| Middle/ High | 84 (45.4) | |
| Baseline HAM-D17 | Mean ± SD | 16.3 ± 4.5 |
Treatment Outcomes
Ninety-nine participants completed 12-week follow-up. HAM-D17 scores declined significantly over time.
Table 2: Change in HAM-D17 Scores Over 12 Weeks (n = 99)
| Time Point | Mean Ham-D17 |
SD |
| Baseline | 16.8 | 4.3 |
| Week 4 | 9.5 | 6.7 |
| Week 8 | 6.9 | 6.4 |
| Week 12 | 3.9 | 4.6 |
Mean reduction at week 12 was 12.9 points (95% CI: 11.2–14.6; p < 0.001). Response was observed in 83.8% and remission in 61.6% of completers.
Subgroup Analysis
Socio-demographic variables were not significantly associated with treatment response.
Table 3: Treatment Response by Socio-demographic Subgroups
| Variable | Subgroup |
Responders n (%)
|
Non-responders n (%) | P |
| Gender | Female | 62 (83.8) | 12 (16.2) | .43 |
| Male | 21 (77.8) | 6 (22.2) | ||
| Residence | Urban | 50 (84.7) | 9 (15.3) | .15 |
| Rural | 33 (73.3) | 12 (26.7) | ||
| Education | ≤ Middle | 39 (73.6) | 14 (26.4) | .18 |
| ≥ Matric | 44 (88.0) | 6 (12.0) |
CGI-S and Discontinuation
CGI-S ratings (n = 30) showed marked improvement, with 86.7% achieving normal or borderline status by week 12.
Table 4: CGI-S Ratings Before and After Treatment (n = 30)
| Initial CGI-S | Final CGI-S | N (%) |
| 4-6 | 1-2 | 26 (86.7) |
| Missing | — | 4 (13.3) |
Early discontinuation occurred in 86 participants, mainly due to loss to follow-up.
Table 5: Reasons for Early Discontinuation (n = 86)
| Reason | N (%) |
| Lost to follow-up | 57 (66.3) |
| Early symptom resolution | 20 (23.3) |
| Adverse effects | 4 (4.7) |
|
Relocation/ change of physician |
5 (5.8) |
Discussion
This study found that a 12-week regimen of 5-hydroxytryptophan (5-HTP), niacin, and pyridoxine was associated with a statistically and clinically significant reduction in depressive symptoms among adults with mild to moderate major depressive disorder. The mean reduction in HAM-D17 scores exceeded established thresholds for clinical relevance and was accompanied by high response and remission rates, comparable to those reported in early antidepressant trials [15,16]. The gradual improvement observed across follow-up visits aligns with known timelines of serotonergic modulation, suggesting a sustained therapeutic effect rather than transient symptom relief [17].
The observed benefit is biologically plausible given the complementary mechanisms of the intervention. 5-HTP directly enhances central serotonin synthesis, while pyridoxine acts as a critical enzymatic cofactor in serotonin production, and niacin supports neuronal energy metabolism through NAD/NADP pathways [8,9,10,11,24]. Deficiencies of B vitamins are common in low-resource settings and have been independently linked to depressive symptoms and impaired neurotransmitter function [11,12,13,14,25]. In this context, a nutraceutical combination may represent a feasible, low-cost adjunct or early intervention for depression, particularly where access to standard pharmacotherapy is limited [19,26]. However, the absence of a control group and high attrition necessitate cautious interpretation, and randomised controlled trials are required to confirm efficacy and safety.
Conclusion
A 12-week regimen of 5-HTP, niacin, and pyridoxine was associated with significant symptom reduction in mild to moderate depression. Controlled trials are required before clinical implementation.
References
[1] World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2021.
[2] Ferrari AJ, Santomauro DF, Mantilla Herrera AM, Shadid J, Ashbaugh C, Erskine HE, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. PLoS Med. 2022;19(7):e1004117.
[3] Malhi GS, Mann JJ. Depression. Lancet. 2022;399(10333):271–284.
[4] Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366.
[5] Cipriani A, Furukawa TA, Nikolakopoulou A, Salanti G, Chaimani A, Atkinson LZ, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of depressive disorder in adults: a systematic review and network meta-analysis. BMJ. 2023;380:e071447.
[6] Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2023;180(2):112–123.
[7] Fava M, Papakostas GI. Antidepressant response: challenges and opportunities. Evid Based Ment Health. 2023;26(1):1–3.
[8] Shaw K, Turner J, Del Mar C, Carter G. Evidence-based psychological treatments for depression: updated review. J Affect Disord. 2023;324:629–637.
[9] Trammell SAJ, Brenner C. NAD⁺ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–132.
[10] Kennedy DO. B vitamins and the brain: mechanisms, dose and efficacy – A review. Nutrients. 2022;14(3):635.
*Rest of the references are available on request
About the authors
Dr Sidra Rasheed – Psychiatry resident; Dr Duaa Fatima – Psychiatry resident; Dr Habib Yazdani – Psychiatry resident; and Professor Imtiaz Dogar are based at the Psychiatry Department, Faisalabad Medical University/Allied Hospital II, Faisalabad.